LDC to Collaborate with Johnson & Johnson Innovation

The Lead Discovery Center GmbH (LDC) and Johnson & Johnson Innovation Ltd., will collaborate to identify and accelerate innovative drug candidates for the treatment and prevention of diseases with high unmet medical needs.

Over a two-year period, LDC and the team from the Johnson & Johnson’s London Innovation Centre will work together to identify on an ongoing basis translational research opportunities sourced from LDC’s top-tier academic network, including institutes from the Max Planck Society, the Helmholtz Association and various universities.

Johnson & Johnson Innovation will review and evaluate the opportunities with the objective of establishing drug discovery collaborations with LDC in selected projects that are aligned with the company’s therapeutic focus areas.

“Through our academic network, we have access to a broad range of exciting molecular targets, pathobiological mechanisms and new therapeutic approaches which are the basis for project proposals with a high innovation potential for drug discovery,” says Dr Bert Klebl, CEO of the LDC. “Together with Johnson & Johnson Innovation, we will now be able to offer a solution for more of our academic partners to translate their innovative findings into benefit for patients. We very much look forward to leveraging our interests, expertise and capabilities together with Johnson & Johnson Innovation to incubate additional collaborative projects at the LDC.”

For each project selected by Johnson & Johnson Innovation, the partners will negotiate a collaboration agreement for its joint development at the LDC up to the next mutually agreed milestone.

The details regarding financial provisions and research activities will be agreed on a project-by-project basis to ensure a fair balance of investments and potential returns between the partners. Any revenue received from commercialization will be shared with the academic inventors and collaborating institutions.

RELATED ARTICLES

A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.

A new study lends further evidence to a suspected link between abnormal breast growth in young boys--called prepubertal gynecomastia--and regular exposure to lavender or tea tree oil, by finding that key chemicals in these common plant-derived oils act as endocrine-disrupting chemicals.

Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.